Glochem adds overall API capacities by 35%. CNS, cardio and diabetes are focus areas in Brazil. Price hike is taken for most of products in Brazil. Approval timelines are 2 years but communication has improved with ANVISA. Mainly, no of ANDA projects going up which includes some dermatology products.īrazil approvals - 3. Currently at around 6% of sales in q1 fy 17. Reconciliation figures according to Indian GAP was for previous quarter. Forecast for market growth is 8-10% for full year.Ĭo’s inventory is 14 days as compared to 19 days for market.
Co expects to grow better than market growth in domestic front. Domestic growth looks poor bcos some products had to be pulled back from the market due to implementation of NLEM guidelines.Ĭo had started to focus on rationalisation (discontinuation of bonus, discounts etc) of domestic biz in q2 last year and the impact of those steps would be comparable post q2 this year.
0 kommentar(er)
